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Abstract
The leishmaniases are vector-borne parasitic diseases with multiple disease pheno-
types that range from self-healing cutaneous ulcers to disfiguring post-kala-azar der-
mal leishmaniasis and fatal visceral leishmaniasis (VL). Infected individuals can develop 
subclinical infections or overt disease. Current treatments are toxic and expensive. The 
only successful control measure is case detection and drug treatment. Resistance to anti-
leishmanial drugs are increasing with few drugs in the pipeline. The Leishmania parasites 
are good candidates for vaccine development, with no change in its antigenic coat and 
extensive cross-reactivity between species. First-generation vaccines are safe, immuno-
genic with inconclusive efficiency. These vaccines presented the leishmanin skin test 
(LST) as a potentially good surrogate marker of immunogenicity/protection that can help 
in future vaccine studies. First-generation vaccines are the only leishmaniasis vaccines 
that progressed to phase III. Second-generation vaccines are safe and immunogenic, but 
none progressed to phase III. Third-generation vaccines recently entered human testing. 
Alternative approaches include in silico prediction of immunogenic Leishmania epitopes 
with in vitro immunogenicity testing. New adjuvants can help in the quest to develop 
efficacious leishmaniasis vaccines. Failure of second- and third-generation vaccines to 
reach phase III, rising drug resistance and continued VL pandemics make it a necessity 
to revisit first-generation vaccines.
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1. Introduction
The leishmaniases are vector-borne, widely prevalent parasitic diseases that are transmitted 
by phlebotomine sand flies. The transmission is either zoonotic or anthroponotic. Together 
with malaria they constitute the most commonly prevalent neglected parasitic diseases. The 
leishmaniases are among the most commonly neglected tropical diseases. The parasite is a 
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unicellular organism that leads to multiple disease phenotypes that range from benign self-
healing cutaneous ulcers to a markedly disfiguring diffuse cutaneous/post-kala-azar dermal 
leishmaniasis and fatal visceral leishmaniasis (VL, kala-azar). Cutaneous leishmaniasis (CL) is 
caused by L. tropica, L. aethiopica, and L. major in the Old World and L. mexicana, L. guyanensis, 
L. amazonensis, and L. braziliensis in the New World. Visceral leishmaniasis is a fatal form of the 
leishmaniasis if not treated. VL is a major health problem and is caused by L. donovani and L. 
infantum that are particularity prevalent in East Africa, the Indian subcontinent, Mediterranean 
Basin, and Latin America [1–9]. The HIV pandemic aggravated further the leishmaniasis mor-
bidity and mortality. Drug treatment with sodium stibogluconate/paromomycin, miltefosine, 
or liposomal amphotericin B is expensive and carries major risks of toxicities. Current control 
measures that include case detection, drug treatment, and insecticide-impregnated bed nets 
are failing as evidenced by repeated epidemics especially in East Africa. In addition, increasing 
drug resistance and geographical expansion of the leishmaniases due to global warming and 
wars make the search for vaccines for the leishmaniases a necessity [2, 10–15].
1.1. Immunity against visceral leishmaniasis
Visceral leishmaniasis is characterized by immune suppression manifesting as pancytopenia 
and anergy to some antigens like Leishmania antigens and purified protein derivative (PPD). 
Following successful drug treatment, a state of immune reconstitution ensues which is char-
acterized by a dermatosis affecting most Sudanese patients known as post-kala-azar dermal 
leishmaniasis (PKDL). Macrophages, CD4+ T cells, CD8+, NK cells, and dendritic cells are 
known to be involved in the immune responses against Leishmania infections. Infection with 
L. donovani parasite can follow two different scenarios: susceptible individuals develop overt 
disease with dissemination of Leishmania parasites through infected macrophages with secre-
tion of IL-4 and IL-10, and nonspecific stimulation of B cells and secretion of large amounts 
of antileishmanial antibodies [Th
2
 immune response]. Alternatively, individuals can develop 
protective immune responses [subclinical infection] with secretion of parasite antigen-spe-
cific IFN-γ, TNF-α by stimulated CD4+ T cells [Th
1
 immune response], and conversion in the 
leishmanin skin test (LST). Eliciting an exact immune response is an important VL vaccine 
requirement that should simulate those induced by natural infection. An important feature of 
an efficacious Leishmania vaccine should be to induce a parasite-specific Th
1
 immune response 
with sufficient amounts of IFN-γ and LST reactivity that should last for life. Induction of 
antileishmanial antibodies by a vaccine should be taken against it, taking into consideration 
that patients with overt diseases secrete large amounts of non-neutralizing antibodies. These 
antibodies have been shown to facilitate the internalization of the Leishmania parasites into 
macrophages [2, 16–19].
1.2. Feasibility of vaccines for the leishmaniases
A vaccine against the Leishmania parasite is a real feasibility, because unlike the plasmodium 
and other parasites, Leishmania rarely changes its antigenic coat. Leishmania infections induce 
lifelong immunity with extensive cross-reactivity between different species of leishmania. 
Therefore, a single vaccine can be potentially effective against many forms of the  leishmaniases. 
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Although the exchange of genetic material between distant Leishmania strains [L. major and 
L. donovani] has recently been raised, this may have some implications for drug treatment, but 
not leishmaniasis vaccine development [20, 21].
1.3. Vaccine biomarkers of immunogenicity, susceptibility, and protection
The ability of vaccines to induce antibody production, Th
1
 (IFN-γ) or Th
2
 (IL-4, IL-10) immune 
response, can be objectively measured for phase II studies. Based on published data, we 
believe that the leishmanin skin test (LST) can be used as a surrogate marker for induction 
of cell-mediated immunity/protection against visceral leishmaniasis in phase II/III studies 
[22–25].
1.4. The leishmanin skin test (LST)
LST is an in vivo skin test that marks Leishmania antigen-specific T-cell responses. The brand 
of LST reagent used in East Africa is an L. major suspension that is manufactured under GMP 
conditions in Pasteur Institute, Iran. The LST has been shown to be a potentially good diag-
nostic aide for the diagnosis of African visceral leishmaniasis (VL) and cutaneous leishmani-
asis (CL) in all age groups in endemic areas. LST reactivity indicates sustained cell-mediated 
immunity, which is nonreactive in patients with VL and becomes reactive 6 months after 
cure. In addition, LST reactivity is a lifelong phenomenon [2, 11, 26]. Individuals with LST 
reactivity do not develop VL as was shown in a two decades follow-up period among the 
large numbers of LST reactive individuals in VL endemic areas in Sudan [2, 27] (Khalil et al., 
personal communication). Evaluation of LST reactivity in endemic areas in East Africa and 
India as reported previously included small sample size and did not specify the duration 
between cure and LST testing. Bern et al. [28] in Bangladesh demonstrated that the frequency 
of LST reactivity increased with increasing duration following cure using L. infantum antigen. 
The Bangladesh study mentioned loss of LST reactivity, but did not show any data about 
population movement that we specifically look at when evaluating LST reactivity from year 
to year. The questions of LST standardization, sensitivity, potency, stability of the Leishmania 
antigens, and longevity of the skin reaction were addressed satisfactory by Weigle and col-
leagues in 1991 [29]. Combination of different Leishmania strains can markedly improve the 
specificity of the LST as was shown previously [28–32]. In conclusion, different Leishmania 
strains in the LST reagent, the inadequate technique (subcutaneous rather than intradermal 
injection), and the time of test reading can greatly affect the outcome and interpretation of 
results of LST. LST is a potentially good surrogate marker of immunogenicity/protection that 
can be useful in future VL vaccine studies.
2. Leishmanization
Leishmanization is a true predecessor of leishmaniasis vaccines; the procedure was practiced 
in Central Asia and the Middle East for times deep in history. Although leishmanization is 
still practiced in some areas, it is considered unsafe and cannot be standardized. Recently, it 
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has been used as a method of evaluation for candidate vaccines [33]. Leishmanization gave 
way to killed or live-attenuated first-generation Leishmania vaccines. Leishmanization like 
first-generation and third-generation vaccines that use genetically modified Leishmania para-
sites or use bacteria and viruses that carry Leishmania genes is daunted by the issue of stan-
dardization [34].
3. First-generation vaccines
First-generation vaccines as whole parasite killed/attenuated were tested in animals and 
humans for cutaneous and visceral leishmaniases. Human studies have to be commended 
despite raised points of standardization and licensure purposes. First-generation vaccines are 
less costly and easy to manufacture. In addition, first-generation vaccines are the only human 
prophylactic VL vaccines that went on to phase III. Khalil and colleagues conducted the first 
human phase III VL vaccine study that was followed by a number of extended phase II stud-
ies on vaccines against visceral leishmaniasis [27]. Although the vaccine was not efficaciously 
different from BCG, important conclusions came out of this study: firstly, the leishmanin 
skin test (LST) is a first potentially good surrogate marker for immunogenicity/protection in 
humans. Secondly, modulation of whole parasite vaccines with strong adjuvants like alum 
markedly improved the immunogenicity of whole parasite vaccine as shown in phase II/
extended phase II studies. Lack of funds under the pretense of poor standardization and 
lack of licensure potentials prevented progression of alum-precipitated Leishmania vaccines 
to phase III [22–25, 35–37].
The future of VL control is bleak based on frequent VL pandemics that kill thousands 
of people in developing countries, increasing drug resistance, lack of new antileishman-
ial drugs in the pipeline, and failure of second-generation vaccines to make it to phase 
III. In view of all the above and the current regulations that prohibit the wide use of whole 
parasites/antigen vaccines, standardization of whole parasite/antigens has to be addressed 
objectively.
Important points have to be highlighted when revisiting first-generation vaccines: the 
Vaccinia [smallpox] vacine which is the first vaccine that helped to eradicate small pox has 
been a whole virus. Furthermore, the control and near elimination of poliomyelitis is suc-
cessful due to the blessing of an attenuated whole virus. Since the above vaccines are consid-
ered fit for human use, whole parasite vaccines have to be given a similar standing especially 
in the era of existing strong adjuvants. Furthermore, the success of immunochemotherapy 
of post-kala-azar dermal leishmaniasis using alum-precipitated autoclaved L. major vaccine 
further supports giving a second chance for first-generation VL vaccines. The inconclusive 
results that were obtained from first-generation vaccine meta-analysis and put it into disre-
pute are probably due to the fact that the analysis included studies for cutaneous as well as 
visceral diseases in the same basket. It has to be clearly stated that these disease phenotypes 
are different with different immune responses and different endpoints of evaluation of effi-
cacy [12, 13, 23, 25, 27, 35, 36, 38–41].
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4. Second-generation vaccines
Second-generation vaccines are recombinant Leishmania antigens (single peptides/polypep-
tides) that are highly purified, amenable to standardization/large-scale production, reproduc-
ibility, and cost-effective production. Safety and immunogenicity have been assured in phase 
I and II studies. But, it is clear that strong adjuvants are needed for these subunit vaccines to 
be satisfactorily immunogenic. Recently, our group tried an alternative cheaper way where 
an in silico approach was employed to predict immunogenic epitopes/peptides of Leishmania 
parasite antigenic coat. The predicted peptides were manufactured commercially and tested 
in an in vitro whole blood system and were shown to be immunogenic [IFN-γ production; no 
IL-10 production]. It was concluded that these peptides can be taken further for prophylactic 
leishmanin vaccine development. Further studies are underway to combine these peptides 
with known and potential adjuvants to increase their immunogenicity [42–49]. In conclusion, 
second-generation VL vaccines will succeed when the mechanisms by which macrophages 
select the most suitable epitopes to induce the appropriate immune response are known.
5. Third-generation vaccines
DNA vaccines came into existence with advances in molecular biology and biotechnology, 
and the injection of small circle of DNA encoding potentially immunogenic proteins became a 
reality [50]. A number of experimental third-generation vaccines have been studied with dem-
onstrated immunogenicity and healing abilities. The first human study for a third-generation 
therapeutic vaccine for visceral leishmaniasis and PKDL was carried out on healthy volunteers 
in the United Kingdom using CHAd63-KH vaccine. The CHAd63-KH vaccine is a replication-
defective simian adenovirus expressing a novel synthetic gene (KH) encoding two Leishmania 
proteins KMP-11 and HASPB. The vaccine was shown to be safe and immunogenic [51–53].
6. Adjuvants for Leishmania vaccines
A plethora of adjuvants, live organisms (BCG), cytokines, oligonucleotide (CpG), minerals 
and particulate lipids, and polymer-based adjuvants are under investigations for Leishmania 
vaccine. Although there is an urgent need for studies on adjuvants in disease-endemic areas, 
access to potent adjuvants is the main hurdle for investigators and researchers in leishmania-
sis-endemic countries [54–61].
7. Conclusion
Failure of second- and third-generation vaccines to reach phase III, rising drug resistance, and con-
tinued devastating VL pandemics make it a necessity to study further first-generation vaccines.
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